Peptides: What You Should Know

Few topics in medicine currently generate as much interest, and as much confusion, as peptides.

They’re discussed everywhere from professional conferences to podcasts, often with bold claims about healing, recovery, and longevity. As interest has grown, so has the misinformation, and the challenge of separating promising science from premature conclusions.

So what exactly are peptides?

Simply put, peptides are short chains of amino acids, the same building blocks that make up proteins throughout the body. Many occur naturally and serve as signaling molecules, helping cells communicate when to repair tissue, regulate inflammation, produce hormones, or carry out countless other biological functions. In fact, some of the most well-established medications in modern medicine, including insulin and GLP-1 medications, are peptide-based medications.

The peptides generating much of today’s attention, however, are compounds such as BPC-157 and TB-500, both of which are being investigated for their potential role in tissue repair and recovery.

Early laboratory and animal research suggests these peptides may influence processes involved in healing, including collagen formation, blood vessel growth, and inflammation. Anecdotally, many patients report improvements in tendon injuries, joint pain, muscle recovery, and other chronic musculoskeletal conditions. While these reports are certainly interesting and deserving of further study, the reality is that high-quality human clinical trials remain limited. At this point, the potential appears promising, but the scale of evidence has not yet caught up with the enthusiasm.

For many clinicians, however, myself included, the biggest concern has been where they currently come from.

Because BPC-157 and TB-500 have not been FDA-approved medications and have historically faced significant restrictions on pharmacy compounding, many patients have turned to products sold online for “research purposes only.” Unfortunately, these products often come with little transparency regarding purity, sterility, dosing accuracy, or manufacturing quality.

That may be beginning to change.

In July 2026, an FDA advisory committee voted to recommend a regulatory pathway that could eventually allow licensed compounding pharmacies to prepare BPC-157, TB-500, and several other peptides by prescription if the FDA ultimately adopts the recommendation.

This is an important distinction. The committee’s vote does not mean these peptides are FDA-approved, nor does it prove they are safe or effective. Those questions still require larger, well-designed human studies. However, if the FDA accepts the recommendation, it could provide a more reliable pathway for obtaining these compounds as opposed to the unregulated marketplace that has existed until now.

As with many emerging therapies, it’s important to separate potential from proof. Peptides like BPC-157 and TB-500 are supported by intriguing early science and encouraging anecdotal reports, but they remain investigational. The recent regulatory developments don’t change the evidence; they simply have the potential to improve how these compounds are sourced and prepared.

Medicine is constantly evolving. The key is remaining open to innovation, disciplined enough to follow the evidence, and transparent enough to acknowledge what we know, what we don’t know, and where the science is headed.

References

ClinicalTrials.gov. (2025). BPC-157 for acute hamstring injury. U.S. National Library of Medicine. https://clinicaltrials.gov/ (ClinicalTrials.gov Identifier: NCT07437547).

Harvard Health Publishing. (2025). Peptides: What they are, potential benefits, and safety concerns. https://www.health.harvard.edu/medications-and-treatments/peptides-what-they-are-potential-benefits-and-safety-concerns

U.S. Food and Drug Administration. (2026). July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

U.S. Food and Drug Administration. (2026). Pharmacy Compounding Advisory Committee briefing document: BPC-157, TB-500, KPV, and MOTS-c. https://www.fda.gov/med ia/193342/download

Reuters. (2026). FDA panel votes to place popular peptide BPC-157 on compounding list. https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-place-popular-peptide-bpc-157-compounding-list-2026-07-23/

Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13. 

Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31(5), 20–24.